Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MM-111 + paclitaxel + trastuzumab
- Development stage
- Phase 1
- Lead developer
- Merrimack Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
MM-111 + paclitaxel + trastuzumab is an investigational combination regimen for the treatment of HER2-positive cancers, particularly gastroesophageal (GE) and gastric adenocarcinomas. MM-111 is a bispecific antibody that targets both HER2 and HER3, forming an inhibitory complex that blocks HER3 and downstream PI3K pathway activation in HER2-overexpressing cancers. Paclitaxel is a microtubule-stabilizing cytotoxic chemotherapeutic. Trastuzumab is a monoclonal antibody that targets the HER2 receptor, inhibiting HER2-mediated signal transduction and inducing antibody-dependent cellular cytotoxicity. Combining these agents aims to enhance antitumor activity by simultaneously inhibiting HER2/HER3 signaling and enhancing cytotoxic effects. The regimen was evaluated in phase I/II trials in HER2-positive GE cancers, but phase II trials were terminated early due to adverse outcomes in overall survival and progression-free survival when MM-111 was added to paclitaxel and trastuzumab[1][3][4].
- Other names
- PTX (for paclitaxel)TRAS (for trastuzumab)
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)MicrotubuleTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on MM-111 + paclitaxel + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MM-111 + paclitaxel + trastuzumab.